Eftilagimod Alfa + Pembrolizumab + Chemotherapy for Lung Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) among adults with metastatic non-small cell lung cancer (NSCLC).Participants will receive either efti plus standard treatment (pembrolizumab and platinum doublet chemotherapy) or placebo plus standard treatment and will be treated for up to 2 years.
Eligibility Criteria
This trial is for adults with advanced or metastatic non-small cell lung cancer (NSCLC) who haven't had systemic therapy for it. They must have a performance status indicating they can carry out daily activities, provide a tumor tissue sample, and expect to live more than 3 months. Participants should agree to contraception guidelines and not be pregnant or breastfeeding.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either efti plus standard treatment (pembrolizumab and chemotherapy) or placebo plus standard treatment for up to 2 years
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Eftilagimod Alfa
Find a Clinic Near You
Who Is Running the Clinical Trial?
Immutep S.A.S.
Lead Sponsor
Merck Sharp & Dohme LLC
Industry Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University